Status:
RECRUITING
Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
Lead Sponsor:
Northwestern University
Collaborating Sponsors:
Sanofi
Conditions:
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Smell Loss
Eligibility:
All Genders
18-65 years
Brief Summary
The goal of this observational study is to learn what can predict the return of the sense of smell in patients with chronic rhinosinusitis with nasal polyps being treated with dupilumab. The main ques...
Eligibility Criteria
Inclusion
- Well documented history of CRSwNP
- BSIT age/sex classified as "abnormal" score
- Self-reported stable olfactory deficit of moderate to severe quality \> 3 months
- Prior endoscopic sinus surgery \>3 months, \<10 years prior
Exclusion
Key Trial Info
Start Date :
May 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06892704
Start Date
May 1 2025
End Date
December 31 2027
Last Update
May 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States, 60611